Rossari Biotech Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dfwowwujk3juim13y5m3q69y.pdf

Key Takeaways


The Q4 Softening: Anomaly vs. Trend

Sunil Chari: "Q2 was an exceptional quarter and Q2 sales, if you see also for all the divisions and if you compare Q2 sales to Q4 sales of all the divisions, you'll find it much lesser. But if you compare the HPPC Q4 with HPPC Q4 last year, you'll still find growth in HPPC."

The Margin Problem: Black-Box Pricing and Raw Material Inflation

Edward Menezes: "With the formulation background, since the ingredients are a kind of a black box for the customer, it becomes very difficult to go to the customer with multiple price increases. So we've been increasing our prices from the quarter of March this year and it is becoming impossible to pass on price increases to customers without them knowing what are the ingredients inside."

Acquisitions: Integration and Cross-Selling


New Product Pipeline: Seeding Future Revenue

Edward Menezes: "The approach here is not about price increase at all, price increase is the easiest way out and is also very easy way to lose your customer or give entry to competitor into the customer."

Exports: A Small Base Growing Fast


Raw Material Environment: Waiting on China and Reliance


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue₹2,000 croreFY23
Consolidated EBITDA₹250 croreFY23
Volume growthAt least 15%FY23
EBITDA margin recoveryReturn to 14-15%By Q2 FY23
Raw material normalizationMaterial situation normalizes, reducing need for further price hikesBy end of Q2 FY23
SAP go-liveOperations live across all group companiesBy end of FY23
EO supply improvementHigher allocation from Reliance expectedFrom July (subject to confirmation)

Key Metrics

MetricQ4 FY22
Consolidated revenue₹439 crore, vs ₹218 crore in Q4 FY21
Standalone organic revenue growth30% YoY
HPPC segment revenue₹304 crore, 69% of total revenue
TSC segment revenue₹110 crore, 25% of total revenue
AHN segment revenue₹25 crore, 6% of total revenue
Consolidated EBITDA₹52 crore, vs ₹35 crore in Q4 FY21
EBITDA margin12%, vs 16% in Q4 FY21
PAT₹24 crore, vs ₹22 crore in Q4 FY21
FY23 consolidated revenue guidance₹2,000 crore
FY23 consolidated EBITDA guidance₹250 crore
Unitop Q4 revenue₹124 crore, 4% growth QoQ
Tristar Q4 revenue₹49.5 crore, about 15% growth QoQ
Unitop Q4 EBITDA marginaround 15%
Tristar Q4 EBITDA marginabout 12%
Standalone HPPC Q4 revenue₹126 crore, vs ₹108 crore in Q4 FY21
Group net cash position₹52 crore
Working capital cyclebelow 60 days
Final dividend per share₹0.5 for FY22
Standalone volume growth FY22in excess of 40%
FY23 volume growth expectationat least about 15%
Target EBITDA margin14%-15%
SAP implementation cost₹3 crore-₹3.5 crore across the group